- Original article
- Open Access
- Published:
Doxycycline poudrage in pleurodesis of malignant pleural effusion: a novel modality for an old agent
Egyptian Journal of Bronchology volume 11, pages 7–10 (2017)
Abstract
Context
Malignant pleural effusion is a common presentation of several malignancies. Chemical pleurodesis is important in its management, but no consensus exists on the optimal agent or methods of pleurodesis.
Aim
This work aimed to evaluate the outcome of oral doxycycline capsules in a poudrage form through a medical thoracoscope as a therapeutic approach for pleurodesis in patients with malignant pleural effusion.
Setting and design
This study was a prospective quasiexperimental one.
Patients and methods
This prospective quasiexperimental study was conducted on 70 patients with metastatic pleural effusion. They underwent pleurodesis with thoracoscopic doxycycline poudrage.
Results
The success of doxycycline powder poudrage was complete in 75.7% of cases and partial in 10% of cases; however, failure was observed in 14.3%. Thus, total success rate was 85.7%. As regards complications, they were irrelevant; pain was the predominant feature in 81.4% of cases, fever in 11.4% of cases, and empyema in only 4.3% of cases.
Conclusion
Using oral doxycycline with thoracoscopic poudrage yielded a remarkable success rate and may alternate the need for talc powder with less complications and more safety.
References
Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J 2001; 18:402–419.
Antunes G, Neville E, Duffy J, Ali N, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58Suppl 2: ii29–ii38.
Sahn SA. Malignant pleural effusions. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Pulmonary disease and disorders. 3rd ed. New York, NY: McGraw-Hill; 1998. 1429–1438.
Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest 2011; 139:1419–1423.
Patz EF Jr, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Gilkeson RC, Herndon J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113:1305–1311.
Mourad IA, Abdel Rahman AR, Aziz SA, Saber NM, Fouad FA. Pleurodesis as a palliative treatment of advanced lung cancer with malignant pleural effusion. J Egypt Natl Canc Inst 2004; 16:188–194.
Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994; 106:1215–1222.
Lee YC, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJ, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 2003; 124:2229–2238.
Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105:1743–1747.
Porcel JM, Salud A, Nabal M, Vives M, Esquerda A, RodrÃguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006; 14:475–478.
Elnady M, Sakr A. Safety and efficacy of pleurodesis with thoracoscopic doxycycline poudrage in malignant pleural effusion. Eur Respir J 2011; 38:55.
Hatata E, Daabis R, ElSabaa B, Baess A, Abd El-Rahman I. Thoracoscopic pleurodesis using doxycycline poudrage in malignant pleural effusion. Chest 2016; 149(4_S):A437.
Diacon AH, Wyser C, Bolliger CT, Tamm M, Pless M, Perruchoud AP, Solèr M Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162(Pt 1):1445–1449.
Hartman DL, Gaither JM, Kesler KA, Mylet DM, Brown JW, Mathur PN. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993; 105:743–747 discussion 747–748.
Statement of the American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1987–2001
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Elhadidy, T.A., Abumossalam, A.M. & Elashry, M.S. Doxycycline poudrage in pleurodesis of malignant pleural effusion: a novel modality for an old agent. Egypt J Bronchol 11, 7–10 (2017). https://doi.org/10.4103/1687-8426.199001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1687-8426.199001
Keywords
- doxycycline poudrage
- malignant pleural effusion
- pleurodesis
- thoracoscopy